<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00972517</url>
  </required_header>
  <id_info>
    <org_study_id>113638</org_study_id>
    <nct_id>NCT00972517</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children</brief_title>
  <official_title>Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (GSK2340272A) in Children Aged 3 to 17 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the immunogenicity and safety of GSK Biologicals'
      investigational vaccine GSK2340272A in children aged between 3 and 17 years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Protocol Posting has been updated following Protocol amendment 1, October 2009. The
      impacted section are the study design section, the outcomes measures section and the
      intervention section.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Humoral immune response in terms of Haemagglutination Inhibition (HI) antibody titers against the Flu A/California/7/2009 (H1N1) vaccine strain</measure>
    <time_frame>At Day 0, Day 21 and Day 42</time_frame>
    <description>Antibody titers were expressed as Geometric mean titers (GMTs).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of seroconverted subjects for HI antibodies against the Flu A/California/7/2009 (H1N1) virus strain</measure>
    <time_frame>At Day 42</time_frame>
    <description>A seroconverted subject was defined as a vaccinated subject with either a pre-vaccination titre less than (&lt;) 1:10 and a post-vaccination titre greater than or equal to (≥) 1:40 or a pre-vaccination titre ≥ 1:10 and at least a 4-fold increase in post-vaccination titre. The Committee for Medicinal Products for Human Use (CHMP) criterion was fulfilled if the point estimate for SCR was greater than (&gt;) 40% in children aged 3 to 17 years.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects who were seroprotected for HI antibodies against the Flu A/California/7/2009 (H1N1) virus strain</measure>
    <time_frame>At Day 42</time_frame>
    <description>A seroprotected subject was defined as a vaccinated subject with a serum HI titre greater than or equal to (≥) 1:40, that usually is accepted as indicating protection. The Committee for Medicinal Products for Human Use (CHMP) criterion was fulfilled if the post-vaccination time point estimate for SPR the point estimate for SPR was greater than (&gt;) 70% in children aged 3 to 17 years.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HI antibody geometric mean fold rise (GMFR) against the Flu A/California/7/2009 (H1N1) virus strain</measure>
    <time_frame>At Day 42</time_frame>
    <description>GMFR, also called seroconversion factor (SCF), was defined as the fold increase in serum HI GMTs post-vaccination compared to pre-vaccination. The CHMP criterion was fulfilled if the point estimate for GMFR was greater than (&gt;) 2.5 in children aged 3 to 17 years</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Humoral immune response in terms of Haemagglutination Inhibition (HI) antibody titers against the Flu A/California/7/2009 (H1N1) vaccine strain</measure>
    <time_frame>At Month 6</time_frame>
    <description>Antibody titers were expressed as geometric mean titers (GMTs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Humoral immune response in terms of Haemagglutination Inhibition (HI) antibody titers against the Flu A/California/7/2009 (H1N1) vaccine strain</measure>
    <time_frame>At Month 12</time_frame>
    <description>Antibody titers were expressed as geometric mean titers (GMTs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of seroconverted subjects for HI antibodies against the Flu A/California/7/2009 (H1N1) virus strain</measure>
    <time_frame>At Month 6</time_frame>
    <description>A seroconverted subject was defined as a vaccinated subject with either a pre-vaccination titre less than (&lt;) 1:10 and a post-vaccination titre greater than or equal to (≥) 1:40 or a pre-vaccination titre ≥ 1:10 and at least a 4-fold increase in post-vaccination titre. The Committee for Medicinal Products for Human Use (CHMP) criterion was fulfilled if the point estimate for SCR was greater than (&gt;) 40% in children aged 3 to 17 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects who were seroprotected for HI antibodies against the Flu A/California/7/2009 (H1N1) virus strain</measure>
    <time_frame>At Month 6</time_frame>
    <description>A seroprotected subject was defined as a vaccinated subject with a serum HI titre greater than or equal to (≥) 1:40, that usually is accepted as indicating protection. The Committee for Medicinal Products for Human Use (CHMP) criterion was fulfilled if the post-vaccination time point estimate for SPR the point estimate for SPR was greater than (&gt;) 70% in children aged 3 to 17 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects who were seroprotected for HI antibodies against the Flu A/California/7/2009 (H1N1) virus strain</measure>
    <time_frame>At Month 12</time_frame>
    <description>A seroprotected subject was defined as a vaccinated subject with a serum HI titre greater than or equal to (≥) 1:40, that usually is accepted as indicating protection. The Committee for Medicinal Products for Human Use (CHMP) criterion was fulfilled if the post-vaccination time point estimate for SPR the point estimate for SPR was greater than (&gt;) 70% in children aged 3 to 17 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HI antibody geometric mean fold rise (GMFR) against the Flu A/California/7/2009 (H1N1) virus strain</measure>
    <time_frame>At Month 6</time_frame>
    <description>GMFR, also called seroconversion factor (SCF), was defined as the fold increase in serum HI GMTs post-vaccination compared to pre-vaccination. The CHMP criterion was fulfilled if the point estimate for GMFR was greater than (&gt;) 2.5 in children aged 3 to 17 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Humoral immune response in terms of neutralising antibodies against the Flu A/Netherlands/602/2009 (H1N1) vaccine strain</measure>
    <time_frame>At Day 0, Day 21, Day 42 and Month 6</time_frame>
    <description>Antibody titers were expressed as Geometric mean titers (GMTs). This analysis was conducted on a subset of one third of the subjects who were randomly selected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Humoral immune response in terms of neutralising antibodies against the Flu A/Netherlands/602/2009 (H1N1) vaccine strain</measure>
    <time_frame>At Month 12</time_frame>
    <description>Antibody titers were expressed as Geometric mean titers (GMTs). This analysis was conducted on a subset of one third of the subjects who were randomly selected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of seroconverted subjects for neutralising antibodies against the Flu A/Netherlands/602/2009 (H1N1) virus strain</measure>
    <time_frame>At Day 21 and Day 42</time_frame>
    <description>A seroconverted subject was defined as a vaccinated subject with either a pre-vaccination titre less than (&lt;) 1:10 and a post-vaccination titre greater than or equal to (≥) 1:40 or a pre-vaccination titre ≥ 1:10 and at least a 4-fold increase in post-vaccination titre. The Committee for Medicinal Products for Human Use (CHMP) criterion was fulfilled if the point estimate for SCR was greater than (&gt;) 40% in children aged 3 to 17 years. This analysis was conducted on a subset of one third of the subjects who were randomly selected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of seroconverted subjects for neutralising antibodies against the Flu A/Netherlands/602/2009 (H1N1) virus strain</measure>
    <time_frame>At Month 6</time_frame>
    <description>A seroconverted subject was defined as a vaccinated subject with either a pre-vaccination titre less than (&lt;) 1:10 and a post-vaccination titre greater than or equal to (≥) 1:40 or a pre-vaccination titre ≥ 1:10 and at least a 4-fold increase in post-vaccination titre. The Committee for Medicinal Products for Human Use (CHMP) criterion was fulfilled if the point estimate for SCR was greater than (&gt;) 40% in children aged 3 to 17 years. This analysis was conducted on a subset of one third of the subjects who were randomly selected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects reporting Any and Grade 3 solicited local symptoms</measure>
    <time_frame>During the 7-day (Days 0-6) post-vaccination period</time_frame>
    <description>Solicited local symptoms assessed were pain, redness and swelling. Any was defined as any solicited local symptom reported irrespective of intensity. Grade 3 pain was defined as significant pain at rest that prevented normal everyday activities as assessed by inability to attend/do work or school or cried when limb was moved/spontaneously painful. Grade 3 redness and swelling was greater than 50 millimeters (mm) i.e. &gt; 50mm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects reporting Any, Grade 3 and Related solicited general symptoms</measure>
    <time_frame>During the 7-day (Days 0-6) post-vaccination period</time_frame>
    <description>Solicited general symptoms assessed were arthralgia, diarrhoea, drowsiness, fatigue, gastro-intestinal symptoms, headache, irritability, loss of appetite, myalgia, shivering, sweating and fever [axillary temperature above 37.5 degrees Celsius (°C)]. Any = any solicited general symptom reported irrespective of intensity and relationship to vaccination. Related = symptoms considered by the investigator to have a causal relationship to vaccination. Grade 3 symptoms = symptoms that prevented normal activity. Grade 3 fever = axillary temperature above 39.0°C.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects reporting any Medically Attended Adverse Events (MAEs)</measure>
    <time_frame>During the entire study period (Day 0 to Month 12)</time_frame>
    <description>MAEs were defined as adverse events with medically-attended visits that were not routine visits for physical examination or vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects reporting any Adverse Events of Specific Interest (AESI)/potential immune-mediated diseases (pIMDs)</measure>
    <time_frame>During the entire study period (Day 0 to Month 12)</time_frame>
    <description>Potential immune-mediated diseases (pIMDs) were defined as a subset of adverse events that included both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which might or might not have an autoimmune etiology. &quot;Any pIMD&quot; was defined as at least one pIMD experienced by the study subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects reporting any, grade 3 and related unsolicited adverse events (AEs).</measure>
    <time_frame>Within the 84-day after the first vaccination or from 63-day follow-up period after the second vaccination</time_frame>
    <description>An unsolicited AE was defined as any AE (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as occurrence of any unsolicited symptom regardless of intensity grade or relation to vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects reporting any and related serious adverse events (SAEs)</measure>
    <time_frame>During the entire study period (Day 0 to Month 12)</time_frame>
    <description>A serious adverse event was any untoward medical occurrence that: resulted in death, was life threatening, required hospitalization or prolongation of hospitalization, resulted in disability/incapacity or was a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination and related was an event assessed by the investigator as causally related to the study vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with normal and abnormal haematological and biochemistry parameters with respect to Alanine aminotransferase (ALAT), Aspartate aminotransferase (ASAT), Total Bilirubin, Bilirubin Conjugated/ Direct,Creatine and Blood urea nitrogen(BUN)</measure>
    <time_frame>At Day 0, Day 21, Day 42 and Month 6 (M6)</time_frame>
    <description>Subjects were categorized by age and according to their results at pre-vaccination (Day 0), Day 21, Day 42 and Month 6 which were below, within and above the normal ranges or unknown</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">245</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receiving alternative dose of GSK23440272A vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK investigational vaccine GSK2340272A</intervention_name>
    <description>Three intramuscular injections</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who the investigator believes that their parent(s)/Legally Acceptable
             Representative(s) (LAR) can and will comply with the requirements of the protocol.

          -  Children, male or female, aged between 3 and 17 years at the time of the first study
             vaccination.

          -  Written informed consent obtained from the subject parent(s) or LAR(s) of the subject.
             Assent obtained from the subject when applicable.

          -  Healthy children as established by medical history and clinical examination when
             entering into the study.

          -  Parent/LAR with access to a consistent means of telephone contact, land line or
             mobile, but NOT a pay phone or other multiple-user device.

        Exclusion Criteria:

          -  Use of any investigational or non-registered product other than the study vaccine
             within 30 days preceding the first dose of the study vaccine or planned use during the
             study period.

          -  Clinically or virologically confirmed influenza infection within six months preceding
             the study start.

          -  Planned administration of any vaccine 30 days prior and 30 days after any study
             vaccine administration.

          -  Chronic administration of immunosuppressants or other immune-modifying drugs within
             three months prior to enrolment in this study or planned administration during the
             study period.

          -  Acute disease and/or fever at the time of enrolment

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition based on
             medical history and physical examination.

          -  Acute or chronic, clinically-significant pulmonary, cardiovascular, hepatic or renal
             functional abnormality, as determined by medical history and physical examination.

          -  Previous administration of any H1N1 A/California-like vaccine.

          -  Administration of immunoglobulins and/or any blood products within the three months
             prior to the enrolment in this study, or planned during the study.

          -  If the subject is female and if she is of childbearing potential, she must practice
             adequate contraception for 30 days prior to vaccination, have a negative pregnancy
             test and continue such precautions for two months after completion of the vaccination
             series.

          -  Any known or suspected allergy to any constituent of influenza vaccines; a history of
             anaphylactic-type reaction to any constituent of influenza vaccines; or a history of
             severe adverse reaction to a previous influenza vaccine.

          -  Known use of an analgesic or antipyretic medication within 12 hours prior to first
             vaccination.

          -  Child in Care.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kehl</city>
        <state>Baden-Wuerttemberg</state>
        <zip>77694</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pforzheim</city>
        <state>Baden-Wuerttemberg</state>
        <zip>75172</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Schwaebisch-Hall</city>
        <state>Baden-Wuerttemberg</state>
        <zip>74523</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stuttgart</city>
        <state>Baden-Wuerttemberg</state>
        <zip>70469</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bindlach</city>
        <state>Bayern</state>
        <zip>95463</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cham</city>
        <state>Bayern</state>
        <zip>93413</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>81241</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Noerdlingen</city>
        <state>Bayern</state>
        <zip>86720</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Frankenthal</city>
        <state>Rheinland-Pfalz</state>
        <zip>67227</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Worms</city>
        <state>Rheinland-Pfalz</state>
        <zip>67547</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 3, 2009</study_first_submitted>
  <study_first_submitted_qc>September 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2009</study_first_posted>
  <disposition_first_submitted>November 17, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>November 17, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 21, 2011</disposition_first_posted>
  <last_update_submitted>October 31, 2016</last_update_submitted>
  <last_update_submitted_qc>October 31, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GSK Bio's influenza vaccine GSK2340272A</keyword>
  <keyword>influenza infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>113638</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113638</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113638</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113638</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113638</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113638</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113638</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <pending_results>
    <submitted>November 8, 2016</submitted>
    <returned>January 6, 2017</returned>
    <submitted>October 30, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

